# 심포지움I

# 미국의 약물사용 안전성 문제와 예방대책

Theresa Mazich, MD

First DataBank, USA

# Medication Safety in the U. S. Evolving Policies and Supporting Technologies

Theresa E. Mazich, MD First DataBank, Inc. San Bruno, California, U.S. A.

Presented at 2003 Annual Meeting of Korean College of Clinical Pharmacy November 22, 2003

# **Medication Safety**

- A systems issue as well as an individual responsibility
- Inadequate safety policies and practices lead to morbidity and mortality
- Inadequate attention to safety can lead to very expensive preventable adverse drug events

# Why the Concern About Medication Safety?

- ~5% of hospital admissions in the United States are connected to drug morbidity and mortality (1)
- 7,000 drug related deaths annually (2)
- In 1995, direct cost of preventable drug morbidity and mortality = US\$76.6 Billion (3)
- In 2000, direct cost of preventable drug morbidity and mortality = US\$177.4 Billion (4)

#### Why the Concern About Medication Safety?

- As doctor reimbursement drops, visit volume increases, visit length decreases, and drugs are substituted for communication
- Aging population = poly-pharmacy
- Empowered consumers demand medications AND quality care
- Government and other payers want to ensure quality of care and guide cost of care

# Where Do Problems Occur?(5)

Medication Use Step and Common Errors	Distribution of Errors by Step	Percentage of ADEs Intercepted	
Prescribing Wrong choice or dose, known allergy	39%	48%	
Transcribing Wrong dose or frequency, missed dose	12%	33%	
<b>Dispensing</b> Wrong dose, drug, or time	11%	34%	
Administering Wrong dose, choice, or drug	38%	2%	

# The Way Forward

- Faced with pervasive medication safety problems, organizations are establishing policies and procedures that:
  - Accept medication errors as a system problem, requiring attention to all steps of medication use
  - Use monitoring, education, and technology

# **Policy and Standards Evolve**

- Drug Utilization Review
- OBRA
- IOM
- ISMP
- Leapfrog (www.leapfroggroup.org)
- California Healthcare Foundation (www.chcf.org)

# **An Intense Focus on Medication Safety**

- We see policies in action:
  - Monitoring
    - DUR
    - Guidelines
    - Committees
  - Education
    - Public notices
    - · confidential notification
  - Technology
    - · Pharmacy, Nursing, and Prescriber software

Let's Focus on Technology Tools......

# **Technology Supports Medication Safety**

#### **Drug Utilization Review:**

- Retrospective DUR: A Very Practical Analysis
  - Shapes clinical and administrative policies supporting drug safety
  - · Identifies clinician educational needs
- Concurrent DUR: Double Checking for Safety
  - Identifies potential medical errors, and avoids preventable ADEs
  - · One medium of clinician education

# **Technology Supports Medication Safety**

- #1Cause of Error: Lack of knowledge of the drug (5)
- 22% of medication errors
- Technologies addressing this cause of error:
  - CPOE, Pharmacy, and Nursing systems using drug knowledge bases that support concurrent DUR

#### **Technology Supports Medication Safety**

- #2 Cause of Error: Lack of information about patients (5)
- 14% of medication errors
- Technologies addressing cause of this error:
  - CPOE, Pharmacy, and Nursing systems with access to critical patient information like lab test results, allergies, conditions, medications, which use drug knowledge bases that support concurrent DUR

# **Technology Supports Medication Safety**

- #3 Cause of Error: Rules Violations (5)
- 10% of medication errors
- Technologies addressing this cause of error:
  - CPOE, Pharmacy, and Nursing systems using drug knowledge bases that standardize care processes with protocols, order sets, guidelines

#### **Technology Supports Medication Safety**

- #4 Cause of Error: Slips and memory lapses (5)
- 9% of medication errors
- Technologies addressing cause of error:
  - CPOE, Pharmacy, and Nursing systems using drug knowledge bases that:
    - Standardize care processes with protocols, order sets, guidelines
    - Screen for allergic cross sensitivity, duplicate therapy, etc.

# **Technology Trends in the U.S.**

- Retail and hospital pharmacies, DUR services, and Pharmacy Benefit Managers currently use software which seeks to detect and prevent medication errors
  - Financially motivated in the beginning
  - Quality care is critical for payers and consumers
- CPOE is on the rise slowly
  - Expensive to implement
  - Requires physician cooperation always a challenge
  - Will offer concurrent DUR at point of prescribing

# Medication Safety as a System Issue

- It is a good approach:
  - Stepping-stone to safer, more effective drug use
  - Culture of communication, not blame, encourages clinician support
  - Significant positive financial implications
  - Time tested
  - A solid foundation for the next generation of medication issues:
    - · Appropriate compliance with drug therapy
    - · Managing chronic disease
    - Raising healthy youth, and caring for our elders

#### **Medication Safety Evolves....**

- · Medication safety is a systems issue
- Preventable medication errors cause morbidity and mortality, and cause great expense
- Policies supporting drug utilization review, system monitoring, communication, and education all help "error proof" drug therapy
- Technology can help "error proof" each step of the drug therapy process, from prescribing, through dispensing, to administration.

Thank you!

#### **Footnotes**

- 1. Einarson TR. "Drug-related hospital admissions."
   Ann Pharmacother. 1993 Jul-Aug;27(7-8):832-40.
- 2. Kohn, LT, Corrigan, JM, and Donaldson, MS, eds., *To Err Is Human: Building A Safer Health System* (Washington, D.C.: National Academy Press, 1999)
- 3.Johnson, JA, Bottman, JL. "Drug-related morbidity and mortality. A cost-of-illness model." Archives of Internal Medicine 1995; 155:
- 4. Ernst FR, Grizzle AJ. "Drug-related morbidity and mortality: updating the cost-of-illness model."
   J Am Pharm Assoc (Wash). 2001 Mar-Apr;41(2):192-9.
- 5. Leape, LL, Bates, DW, Cullen, DJ, et al. "Systems analysis of adverse drug events" JAMA 1995; 274: 35-43